Response to Imatinib Rechallenge of GIST That Recurs Following Completion of Adjuvant Imatinib Treatment - the First Analysis in the SSGXVIII/AIO Trial Patient Population

被引：13
|
作者：
Reichardt, P. [1 ]
Hartmann, J. T. [2 ]
Hall, K. Sundby [3 ]
Eriksson, M. [4 ]
Schuette, J. [5 ]
Ramadori, G. [6 ]
Hohenberger, P. [7 ]
Duyster, J. [8 ]
Leinonen, M. [9 ]
Joensuu, H. [10 ]
机构：
[1] HELIOS Klinikum Bad Saarow, Sarcoma Ctr Berlin Brandenburg, Bad Saarow Pieskow, Germany
[2] Univ Tubingen, Med Oncol Hematol Immunol Rheumatol & Pulmonol, Med Ctr, Tubingen, Germany
[3] Norwegian Radium Hosp, Oslo Univ Hosp, Oncol, Oslo, Norway
[4] Lund Univ, Skane Univ Hosp, Oncol, Lund, Sweden
[5] Marien Hosp, Oncol Hematol, Dusseldorf, Germany
[6] Univ Gottingen, Gastroenterol Endocrinol, D-37073 Gottingen, Germany
[7] Univ Mannheim, Med Ctr, Surg Oncol Thorac Surg, D-68131 Mannheim, Germany
[8] Tech Univ Munich, Klinikum Rechts Isar, Internal Med 3, D-80290 Munich, Germany
[9] 4Pharma Ltd, Turku, Finland
[10] Univ Helsinki, Cent Hosp, Oncol, Helsinki, Finland
来源：
EUROPEAN JOURNAL OF CANCER | 2011年 / 47卷
关键词：
D O I：
10.1016/S0959-8049(11)70130-7
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
31LBA
引用
收藏
页码：15 / 15
页数：1
相关论文
共 35 条
  • [1] Twelve versus 36 months of adjuvant imatinib (IM) as treatment of operable GIST with a high risk of recurrence: Final results of a randomized trial (SSGXVIII/AIO).
    Joensuu, H.
    Eriksson, M.
    Hatrmann, J.
    Hall, K. Sundby
    Schutte, J.
    Reichardt, A.
    Schlemmer, M.
    Wardelmann, E.
    Ramadori, G.
    Al-Batran, S.
    Nilsson, B. E.
    Monge, O.
    Kallio, R.
    Sarlomo-Rikala, M.
    Bono, P.
    Leinonen, M.
    Hohenberger, P.
    Alvegard, T.
    Reichardt, P.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (18)
  • [2] Twelve versus 36 months of adjuvant imatinib (IM) as treatment of operable GIST with a high risk of recurrence: Final results of a randomized trial (SSGXVIII/AIO).
    Joensuu, H.
    Eriksson, M.
    Hatrmann, J.
    Hall, K. Sundby
    Schutte, J.
    Reichardt, A.
    Schlemmer, M.
    Wardelmann, E.
    Ramadori, G.
    Al-Batran, S.
    Nilsson, B. E.
    Monge, O.
    Kallio, R.
    Sarlomo-Rikala, M.
    Bono, P.
    Leinonen, M.
    Hohenberger, P.
    Alvegard, T.
    Reichardt, P.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [3] Three vs. 1 year of adjuvant imatinib (IM) for operable high-risk GIST: The second planned analysis of the randomized SSGXVIII/AIO trial
    Joensuu, Heikki
    Eriksson, Mikael
    Hall, Kirsten Sundby
    Reichardt, Annette
    Ramadori, Giuliano
    Hohenberger, Peter
    Al-Batran, Salah-Eddin
    Schlemmer, Marcus
    Bauer, Sebastian
    Pink, Daniel
    Duyster, Justus
    Nilsson, Bengt E.
    Monge, Odd R.
    Kallio, Raija
    Bono, Petri
    Junnila, Jouni
    Wardelmann, Eva
    Alvegard, Thor
    Reichardt, Peter
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [4] Neoadjuvant Imatinib in Gastrointestinal Stromal Tumors (GIST): The First Analysis of a Mexican Population
    Guzman, Rafael Medrano
    Lara, Xavier Lopez
    Rivera, Atl Simon Arias
    Rios, Luis. E. Garcia
    Chaoul, Moises Brener
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2024, 16 (07)
  • [5] Response to imatinib rechallenge in a patient with a recurrent gastrointestinal stromal tumor after adjuvant therapy: A case report
    Kang Y.-K.
    Journal of Medical Case Reports, 5 (1)
  • [6] ALT-GIST: Randomized phase II trial of imatinib alternating with regorafenib versus imatinib alone for the first-line treatment of metastatic gastrointestinal stromal tumor (GIST).
    Yip, Desmond
    Zalcberg, John Raymond
    Blay, Jean-Yves
    Eriksson, Mikael
    Espinoza, David
    Price, Timothy Jay
    Marreaud, Sandrine
    Italiano, Antoine
    Steeghs, Neeltje
    Boye, Kjetil
    Underhill, Craig
    Naher, Sayeda
    Oostendorp, Martinus
    Gebski, Val
    Simes, John
    Gelderblom, Hans
    Joensuu, Heikki
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [7] Efficacy and safety of sunitinib ina worldwide treatment-use trial of gist patients following imatinib failure
    Kang, Y.
    Reichardt, P.
    Ruka, W.
    Seddon, B.
    Baum, C.
    Demetri, G.
    ANNALS OF ONCOLOGY, 2007, 18 : VII16 - VII16
  • [8] Imatinib alternating with regorafenib compared to imatinib alone for the first-line treatment of advanced gastrointestinal stromal tumor: The AGITG ALT-GIST intergroup randomized phase II trial
    Yip, Desmond
    Zalcberg, John
    Blay, Jean-Yves
    Eriksson, Mikael
    Espinoza, David
    Price, Timothy
    Marreaud, Sandrine
    Italiano, Antoine
    Steeghs, Neeltje
    Boye, Kjetil
    Underhill, Craig
    Gebski, Val
    Simes, John
    Gelderblom, Hans
    Joensuu, Heikki
    BRITISH JOURNAL OF CANCER, 2025,
  • [9] Treatment of gastrointestinal tumor (GIST) of the rectum requiring abdominoperineal resection following neoadjuvant imatinib: a cost-effectiveness analysis
    Farid, Mohamad
    Ong, Johnny
    Chia, Claramae
    Tan, Grace
    Teo, Melissa
    Quek, Richard
    Teh, Jonathan
    Matchar, David
    CLINICAL SARCOMA RESEARCH, 2020, 10 (01)
  • [10] Cost-utility analysis of adjuvant imatinib treatment in patients with high risk of recurrence after gastrointestinal stromal tumour (GIST) resection in Thailand
    Bussabawalai, Thanaporn
    Thiboonboon, Kittiphong
    Teerawattananon, Yot
    COST EFFECTIVENESS AND RESOURCE ALLOCATION, 2019, 17 (1)
1234